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ABSTRACT 1
The role that vitamin D plays in pulmonary function remains uncertain. Epidemiological studies 2 reported mixed findings for the association of serum D] and 3 pulmonary function. We conducted the largest cross-sectional meta-analysis of the 25(OH)D-4 pulmonary function association to date, based on nine European ancestry (EA) cohorts 5 (n=22,838) and five African ancestry (AA) cohorts (n=4,290) in the CHARGE Consortium. Data 6 were analyzed using linear models by cohort and ancestry. Effect modification by smoking status 7 (current/former/never) was tested. Results were combined using fixed-effects meta-analysis. 8
Mean (SD) serum 25(OH)D was 68 (29) nmol/L for EAs and 49 (21) nmol/L for AAs. For each 9 1 nmol/L higher 25(OH)D, forced expiratory volume in the first second (FEV 1 ) was higher by 10 1.1 mL in EAs (95% CI: 0.9,1.3; P=2.5×10 -21 ) and 1.8 mL (95% CI: 1.1,2.5; P=1.6×10 -7 ) in AAs 11 (P race difference =0.06), and forced vital capacity (FVC) was higher by 1.3 mL in EAs (95% CI: 12 1.0,1.6; P=1.1×10 -20 ) and 1.5 mL (95% CI: 0.8,2.3; P=1.2×10 -4 ) in AAs (P race difference =0.56). 13
Among EAs, the 25(OH)D-FVC association was stronger in smokers: per 1nmol/L higher 14 25(OH)D, FVC was higher by 1.7 mL (95% CI: 1.1,2.3) for current smokers and 1.7 mL (95% 15 CI: 1.2,2.1) for former smokers, compared to 0.8 mL (95% CI: 0.4,1.2) for never smokers. In 16 summary, the 25(OH)D associations with FEV 1 and FVC were positive in both ancestries. In 17
EAs, a stronger association was observed for smokers compared to never smokers, which 18 supports the importance of vitamin D in vulnerable populations. 19
Keywords: 25-hydroxyvitamin D; vitamin D; forced expiratory volume; vital capacity; 20 respiratory function tests; smoking; human; adult; whites; African Americans. 21
INTRODUCTION 22
Chronic obstructive pulmonary disease (COPD), the third leading cause of mortality in the 23 U.S. (1) and among the top 10 leading causes of total years of life lost in the world (2) , is 24 characterized by progressive airway obstruction. Pulmonary function tests (PFTs), as performed 25 by spirometry, are used to quantify pulmonary function parameters including forced expiratory 26 volume in the first second (FEV 1 ) and forced vital capacity (FVC). Pulmonary function increases 27 throughout childhood, plateaus in the 20s, and thereafter adults experience an age-related 28 decline (3) . The majority of COPD cases (85%) are related to smoking (4) , which alters the 29 trajectory in pulmonary function, by hindering growth, reducing peak function, and accelerating 30 age-related decline (5) . 31
Vitamin D is proposed to have protective effects in the lungs via gene regulation (6) . In vitro 32 studies found that 1,25-dihydroxyvitamin D, the active vitamin D metabolite, induced 33 antimicrobial peptides for host defense in the lung and modulated airway remodeling (7) . In 34 humans, D] is the major vitamin D metabolite in serum, most of 35 which forms a complex with vitamin D binding protein (~85-90% is DBP-bound) (8) , and then is 36 metabolized to 1,25-dihydroxyvitamin D [1, 2 D], the active steroid hormone form (8, 9) . 37 Total 25(OH)D is the commonly used biomarker of vitamin D status, and it is preferred to other 38 vitamin D metabolites, such as non-DBP-bound 25(OH)D and 1,25-(OH) 2 D, given that it is a 39 comprehensive indicator for vitamin D stores, has a longer half-life (~3 weeks) and is less 40 affected by calcium (10, 11) . On average, African ancestry (AA) populations have lower serum 41 25(OH)D concentrations, due to multiple factors including genetics and skin pigmentation (7) , but 42 there is evidence that AA populations have higher 1,25-(OH) 2 D levels and greater bone mineral 43 density compared to European ancestry (EA) populations (12) . 44 Previous observational cross-sectional studies of the vitamin D-pulmonary function association 45 in the general population reported mixed findings. Most of these studies reported a positive 46 association between 25(OH)D and pulmonary function (13) (14) (15) (16) (17) (18) (19) , although some reported a null or 47 inverse association (20) (21) (22) , and two others reported a positive association under certain conditions, 48 such as only in male current smokers (23) or only in overweight and obese males (24) . The largest 49 previous cross-sectional study, which included two Danish cohorts (total n = 18,507), reported 50 positive associations of 25(OH)D with pulmonary function (16) . Only one prior cross-sectional 51 study investigated serum 25(OH)D and pulmonary function in an ancestry group other than 52 European, and it confirmed similar positive associations in the 3,957 AA participants studied (13) . 53
The current study investigated the hypothesis that serum 25(OH)D level is positively associated 54 with pulmonary function. We leveraged the Cohorts for Heart and Aging Research in Genomic 55 Epidemiology (CHARGE) Consortium to include population-based data on serum 25(OH)D and 56 pulmonary function in a harmonized analysis. Additionally, we compared the association of 57 serum 25(OH)D and pulmonary function across EA and AA groups and investigated effect 58 modification by cigarette smoking. 59
MATERIALS AND METHODS 60

Cohorts and Participants 61
Nine prospective cohorts in the CHARGE Consortium were included ( Table 1) . All cohorts had 62 EA participants, and five of the cohorts had AA participants. Only one cohort Study of Atherosclerosis (MESA)] has participants with other ancestries, and these other 64 ancestries were not included in this study. Among the nine cohorts, the Framingham Heart Study 65 (FHS) had two sub-cohorts analyzed separately: the Offspring and the Third-Generation (Gen3) 66 cohorts. Our analysis pipeline harmonized the outcome and exposure definitions, the units on all 67 variables, and the statistical modeling. The same exclusion criteria were applied to each cohort: 68 missing PFTs, unacceptable PFTs using the American Thoracic Society and European 69 Respiratory Society criteria for acceptability, missing serum 25(OH)D, serum 25(OH)D > 374.4 70 nmol/L (or 150ng/mL, leading to removal of a single outlier) (25) , or missing on other covariates 71 (Supplemental Table 1 ). 72
Outcome and Exposure Assessment 73
Pre-bronchodilator pulmonary function outcomes (FEV 1 , FVC, and FEV 1 /FVC), which have 74 similar accuracy as post-bronchodilator measures for long-term outcomes (26) , were measured in 75 each cohort using standardized methods defined by the American Thoracic Society/European 76 Respiratory Society criteria (Supplemental Table 2 ). The methods used to measure 25(OH)D 77 varied by cohort (Supplemental Table 2 (27) , which reflects the calendar time of 86 the measurements in the cohorts, most of which occurred before the availability of the standard 87 reference material (Supplemental Table 3 ). CARDIA measured serum vitamin D in a subset of 88 participants included in an ancillary study of bone mineral homeostasis (28) . For the remaining 89 cohorts, measurements of the outcome and exposure variables were planned for either the full 90 cohort or a random sample (Supplemental Table 1 ). Continuous variables were used for serum 91 25(OH)D and pulmonary function to capture the association of 25(OH)D on PFTs across the 92 broad distribution of ranges in the cohorts. 93
As shown in Table 1 Other covariates, including smoking status, pack-years (number of packs of cigarettes smoked 99 per day times the number of years smoked), height, weight, and age, were measured concurrently 100 with pulmonary function, except for CHS, which assessed covariates concurrent with the serum 101 25(OH)D measure, but within 1 year of the PFT measurement (Supplemental Table 3 ). All data 102 collection and analysis was approved by the Institutional Review Board at each cohort's 103 respective institution. Spirometry measures are available on the database of Genotypes and 104
Phenotypes via accession numbers as follows: ARIC (phs000280), CARDIA (phs000285), CHS 105 (phs000287), FHS (phs000007), and MESA (phs000209). Serum vitamin D measures are also 106 available at the same accession numbers for CHS, FHS, and MESA. 107
Statistical Analysis in Individual Cohorts 108
All analyses were first conducted independently in each cohort, stratified by ancestry, given the 109 lower mean serum 25(OH)D level in AA participants (7) . For FEV 1 and FEV 1 /FVC, models were 110 adjusted for smoking status, pack-years, height, height squared, age, age squared, sex, season of 111 blood draw, and study center (if applicable); for FVC, the model was further adjusted for weight. 112
Residual outliers, identified using the studentized residuals of the linear models (Supplemental 113 Methods for more details), were excluded from all models. The model was extended to test the 114 interaction between 25(OH)D and smoking status [never (reference group), former, and current 115 smokers]. 116
Meta-Analysis 117
Fixed-effects meta-analysis was conducted for the association of serum 25(OH)D on each PFT 118 outcome for each ancestry group, using inverse variance weighting, with heterogeneity assessed 119 via the I 2 statistic (29) . The comparison of meta-analyzed coefficients of the 25(OH)D-PFT 120 associations for the two ancestry groups was conducted using a Z test (30) . Meta-analysis of the 121 interaction terms of 25(OH)D with smoking status was also performed (Supplemental Methods 122 for more details). 123
Meta-regression was conducted to explore the potential causes of heterogeneity in the primary 124 meta-analysis of serum 25(OH)D on FEV 1 (or FVC) in EAs. Modifiers were tested individually 125 in the meta-regression models to investigate heterogeneity; modifiers included factors that could 126 vary between cohorts, such as proportion of ever, current, and former smokers, mean 25(OH)D 127 level, assay method for serum 25(OH)D, time between 25(OH)D and PFT measures, and mean 128 age of participants in each cohort. The two-sided type I error was examined at 0.05 for all 129 analyses. Meta-analysis and meta-regression were conducted using the metafor package (version 130 1.9-8) in R (version 3.2.3., R Foundation for Statistical Computing, Vienna, Austria). 131
RESULTS 132
We studied 22,838 EA and 4,290 AA participants. EA participants had higher FEV 1 , FVC, and 133 serum 25(OH)D than AA participants in each cohort, while FEV 1 /FVC was similar across 134 ancestry groups (Table 1 and Supplemental Figure 1) . CARDIA and FHS-Gen3 were younger 135 than the seven other cohorts, with consequently lower pack-years smoked in ever smokers. 136 Across all cohorts, among EA participants, 17% were current smokers and 40% were former 137 smokers; among AA participants, 22% were current smokers and 30% were former smokers. The 138 serum 25(OH)D level was highest among never smokers [mean(SD) = 70 (30) PFT outcomes, FEV 1 and FVC, in both ancestry groups. To put these findings into context, a 10 151 nmol/L (~0.5 SD) higher 25(OH)D was associated with 11.1 mL higher FEV 1 in EAs (P = 152 2.5×10 -21 ) and 17.9 mL higher FEV 1 in AAs (P = 1.6×10 -7 ) . Similarly, for a 10 nmol/L higher 153 25(OH)D, FVC was higher by 12.9 mL in EAs (P = 1.1×10 -20 ) and by 15.4 mL in AAs (P = 154 1.2×10 -4 ). The magnitudes of the 25(OH)D-PFT associations did not differ significantly between 155 the two ancestry groups (P = 0.06 and P = 0.56 for FEV 1 and FVC, respectively). The association 156 of serum 25(OH)D with FEV 1 /FVC reached statistical significance only in EAs (P = 0.0013), 157 and the magnitude was negligible; a 10 nmol/L higher 25(OH)D was associated with a ratio 158 being lower by 0.0055% (Supplemental Table 4 and Supplemental Figure 2 for ancestry-and 159 cohort-specific findings). 160
In the main-effect meta-analysis of serum 25(OH)D on pulmonary function, there was low to 161 moderate heterogeneity in the EA cohorts, and low heterogeneity in the AA cohorts (Figure 1,  162 Supplemental Figure 2) . We used meta-regression to explore potential causes of moderate 163 heterogeneity in the meta-analysis of 25(OH)D on FEV 1 and FVC in the EA cohorts. Cohorts 164 with lower mean 25(OH)D concentration had stronger 25(OH)D-PFT associations (Figure 2) . 165
The proportion of ever smokers and of former smokers had significant linear associations with 166 the 25(OH)D-PFT coefficients (Supplemental Figure 3) , and these two variables were both 167 highly correlated with mean 25(OH)D levels (Pearson's r > 0.75 for all pairwise correlations). 168
The 25 To examine the potential impact of family relatedness between the FHS-Gen3 and the FHS-175
Offspring cohorts on the meta-analysis, sensitivity analysis confirmed that the findings were 176 unchanged when either cohort was excluded (results not shown). 177
Cohort-specific findings (Supplemental Table 5 and 6) from models that included the 25(OH)D 178 × smoking status interaction terms were combined in secondary meta-analyses (Supplemental 179 Table 7 ). In the EA cohorts, 25(OH)D had a greater positive association with FVC in current 180 smokers than in never smokers (β current × 25(OH)D = 7.5 mL for 10 nmol/L increment of 25(OH)D, P 181 = 0.047). Similarly, 25(OH)D had a greater positive association with FVC in former smokers 182 than in never smokers (β former × 25(OH)D = 7.9 mL for 10 nmol/L increment of 25(OH)D, P = 183 0.0065) (Figure 3) . For the FEV 1 outcome in the EA cohorts, the interaction coefficients for 184 25(OH)D and smoking status had the same positive direction as the coefficients for FVC, but 185 were not statistically significant for either current (P = 0.14) or former smokers (P = 0.14). There 186 was no statistical evidence of interaction of 25(OH)D and cigarette smoking in the AA cohorts 187 for either outcome. To put the interaction finding into context, a 10 nmol/L higher serum 188 25(OH)D was associated with a 17.3 mL higher FVC in current smokers and a 16.6 mL higher 189 FVC in former smokers, which was more than double the association magnitude in never 190 smokers (β = 7.8 mL). A similar trend was found for the FEV 1 outcome in the EA cohorts. For 191 10 nmol/L higher serum 25(OH)D, FEV 1 was higher by 14.0 mL in current smokers, 12.0 mL in 192 former smokers, and 8.0 mL in never smokers (Figure 4) . 193
DISCUSSION 194
This study investigated the association of serum 25(OH)D with pulmonary function using 195 multiple cohorts of different ancestries. We found a consistently positive association of serum 196 25(OH)D with FEV 1 and FVC across both EA and AA groups. In addition, in the EA group, a 197 significantly stronger association was observed for current and former smokers, compared to 198 never smokers. 199
A previous cross-sectional study in a European ancestry population (two Copenhagen cohorts: n 200 = 10,116 and n = 8,391 respectively) similarly reported positive associations of 25(OH)D with 201 FEV 1 percentage predicted and FVC percentage predicted, but not with FEV 1 /FVC (16) . The 202 magnitude of the association was about four times greater in the Copenhagen study, which may 203 be due to the difference in the mean serum 25(OH)D (Danish median ~42 nmol/L vs. CHARGE 204 median of ~65 nmol/L) given our finding that the 25(OH)D-PFT association was stronger in 205 cohorts with lower serum 25(OH)D. Our finding for the serum 25(OH)D-FEV 1 association was 206 similar in magnitude to the association reported in a British cohort of 6,789 participants with an 207 average age of 45 years (17) , but weaker than a previous report from the FHS cohort (15) . Given that 208 the rate of decline in FEV 1 at age 45 is increased by ~15 mL/year in current smokers (31) , we 209 estimate that a 10 nmol/L higher 25(OH)D is similar to approximately 1 year of current 210 smoking-related decline in FEV 1 for both ancestries, but in the opposite direction. Potential 211 biological mechanisms for a causal association between low 25(OH)D levels and low pulmonary 212 function include an altered immune response that increases susceptibility to inflammation, a 213 reduction in pulmonary parenchyma related to extracellular matrix homeostasis important for 214 lung structure, and/or a decrease in serum calcium that could adversely affect thoracic skeleton 215 mobility and respiratory muscle performance (32) . 216
Our findings show that the association of serum 25(OH)D with FEV 1 and FVC were stronger in 217 magnitude in AA versus EA participants, although the difference by race did not reach statistical 218 significance. The finding may reflect the lower serum 25(OH)D in AA participants, which is 219 consistent with the meta-regression finding and with a previous study reporting attenuated 220 associations at higher serum 25(OH)D (15) . Future studies that investigate genetic variation in 221
EAs and AAs in the context of serum 25(OH)D may help explain the differences. 222
In EA participants, the positive interaction terms between serum 25(OH)D and smoking status 223 supported a stronger magnitude of association of serum 25(OH)D with FVC in current and 224 former smokers than in never smokers, with a consistent, but not statistically significant, 225 difference for FEV 1 . The interaction finding is consistent with a prior cross-sectional National 226
Health and Nutrition Examination Survey (NHANES) study, which reported a stronger 227 25(OH)D-FEV 1 association in current and former smokers than in never smokers that was near 228 statistical significance (P = 0.06) (13) . Given smokers have a higher level of oxidative stress and 229 lower pulmonary function than never smokers, partly due to chronic inflammation in lung tissue, 230 the stronger protective association of 25(OH)D on pulmonary function in smokers suggests a 231 benefit for smokers. To explore this interaction, estimates of the 25(OH)D-PFT association were 232 computed within each smoking category. In EA participants, the 25(OH)D-FEV 1 (or FVC) 233 associations were statistically significant in all strata. Generally, in ever smokers of European 234 ancestry, the coefficients for 25(OH)D were greater for FVC than for FEV 1 . 235 Meta-regression provided additional evidence for effect modification by smoking. The 236 proportion of ever smokers was a significant modifier of the association of serum 25(OH)D with 237 FEV 1 and FVC. The higher the proportion of ever smokers, the greater the 25(OH)D-PFT 238 association. More specifically, the proportion of former smokers explained the heterogeneity in 239 the 25(OH)D-PFT association across cohorts more fully than the proportion of current smokers; 240 this may be explained by a survival bias in older participants who were current smokers. The 241 meta-regression based on mean age of the cohorts yielded findings that were consistent with a 242 prior NHANES study that showed the association of 25(OH)D and FEV 1 was greater in people 243 over age 60 compared to younger individuals (13) . 244
There are several methodological considerations in interpreting the findings of this study. First, 245 the meta-regression showed stronger 25(OH)D-PFT associations in cohorts with lower mean 246 serum 25(OH)D, indicating a non-linear 25(OH)D-PFT association. This finding is consistent 247 with a prior study in the FHS cohort, which reported a non-linear association and a stronger 248 25(OH)D-FEV 1 association in participants at risk of vitamin D deficiency (< 30 nmol/L) (15) . 249
Second, serum 25(OH)D was measured by four different methods across the cohorts. For 250 example, two cohorts with high mean 25(OH)D (> 90 nmol/L) used RIA methods. These same 251 cohorts had a lower magnitude estimate of the 25(OH)D-PFT association; if the higher mean 252 represents the 'truth' (and is not caused by measurement error in the RIA assay), then the lower 253 25(OH)D-PFT association may be primarily driven by the vitamin D distribution and not by the 254 RIA method. Whether the assay method itself directly influences the estimate of the 25(OH)D-255 PFT association requires further data. Third, in this cross-sectional meta-analysis, there were 256 minor differences in the time separation between the measurement of serum 25(OH)D and 257 pulmonary function, but the meta-regression test for heterogeneity confirmed that time 258 separation between measurements did not affect the 25(OH)D-PFT associations. Indeed, past 259 studies with longitudinal measurements of serum 25(OH)D reported a high correlation of 260 25(OH)D measurements over a long period of time, with a correlation coefficient of 0.7 for 261 measurements separated by 1 year, 0.5 for measurements separated by 5 years (33) , and 0.42-0.52 262 for measurements separated by 14 years (34) , which supports the use of a single 25(OH)D 263 measurement to represent usual level. Fourth, residual confounding was unlikely given the 264 consistent results across multiple cohorts in various settings. Weight was adjusted for the FVC 265 outcome, given that higher weight and adiposity negatively affects lung volume (i.e., FVC) (35) ; 266 weight was not adjusted in the FEV 1 models, given FEV 1 is a measure of airways obstruction 267 and not physical restriction of lung volume. Physical activity was not adjusted because it is not a 268 confounder in estimating the serum 25(OH)D-PFT association; while physical activity is known 269 to contribute to oxygen utilization in lungs (36) there is little evidence and no biological rationale 270 for a causal association of physical activity with either FEV 1 or FVC (37) , which are markers for 271 airways obstruction and lung volume, respectively. Finally, we do not expect selection bias to 272 affect the estimate of the serum vitamin D-PFT association in this meta-analysis; the association 273 magnitude and direction was consistent across all cohorts, regardless of the proportion of the 274 original cohort contributing to the analysis. Thus, selection bias is expected to be negligible and 275 would likely lead to an underestimated association, given the participants retained in the cohorts 276 are expected to be, on average, healthier than those who were lost to follow-up. 277 This study meta-analyzed the serum 25(OH)D-PFT association across nine cohorts, according to 278 a common pipeline that harmonized the variables and statistical analysis. The sample size 279 comprised 17,569 EA participants from the United States; 5,269 EA participants from Iceland 280 and the Netherlands; and 4,290 AA participants from the United States, all of whom were 19 to 281 95 years old. The sample provided excellent representation of the U.S. population, based on 282 comparisons of demographic factors including sex, height, weight, smoking status, and COPD 283 prevalence (~6.1%) to national surveys (38) (39) (40) , which strengthens the external validity of the 284 study 's findings. 285 In summary, using meta-analysis, we estimated a positive association of serum 25(OH)D with 286 the pulmonary function parameters FEV 1 β (unit: mL) denotes that 1 nmol/L higher serum 25(OH)D was associated with a β mL higher FEV 1 (or FVC), calculated from an analysis including the interaction of serum 25(OH)D and smoking status. The error bar represents ± 1 standard error. We used 22,787 EA participants for the FEV 1 outcome and 22,777 EA participants for the FVC outcome. Abbreviation: 25(OH)D, 25-Hydroxyvitamin D; EA, European Ancestry; FEV 1 , Forced Expiratory Volume in the First Second; FVC, Forced Vital Capacity; PFT, Pulmonary Function Test. 
